MedPath

Tagged News

CorestemChemon Partners with ATG Lifetech to Advance Organoid-Based Preclinical Testing

Drug Discovery
  • CorestemChemon, a GLP-certified preclinical CRO from South Korea, has formed a strategic partnership with ATG Lifetech to deliver transcriptomics-powered, organoid-based preclinical testing services globally.
  • The collaboration will develop disease-relevant organoid models for liver, heart, and blood-brain barrier applications, offering up to 5x greater predictive accuracy compared to conventional 2D cell cultures.
  • The partnership aims to provide high-throughput transcriptomics analytics for tumorigenicity studies and regulatory-aligned expertise for FDA/EMA pathways across the US, Europe, and Asia.
  • Revenue-generating service offerings are expected to begin by late 2025, with joint research outputs to be showcased at a major toxicology conference in Q4 2025.

Champions Oncology Appoints Rob Brainin as New CEO to Drive Data Platform Expansion

Leadership ChangeDrug Discovery
  • Champions Oncology has appointed Rob Brainin as Chief Executive Officer effective August 25, 2025, succeeding Dr. Ronnie Morris who will transition to Executive Chair.
  • Brainin brings over 25 years of life sciences experience, most recently serving as Chief Business Officer at Veracyte and previously as CEO of Genuity Science.
  • The leadership change positions Champions to expand beyond core CRO services into robust data offerings and advance its discovery therapeutics subsidiary, Corellia AI.
  • Dr. Morris, who led the company since 2017, will remain actively involved in strategic initiatives while supporting the leadership transition.

10x Genomics Partners with Singapore Institute to Launch AI-Driven Cancer Drug Discovery Study

AIDrug DiscoveryPrecision Medicine
  • 10x Genomics and A*STAR Genome Institute of Singapore announced the TISHUMAP project, an ambitious collaboration to analyze up to 2,500 clinical tissue samples using AI and spatial biology technology.
  • The study will focus on gastric, liver, and colorectal cancers, utilizing 10x Genomics' Xenium platform to visualize gene activity within individual cells in intact tissues.
  • The collaboration aims to accelerate drug target discovery and enable precision medicine by identifying novel biomarkers and therapeutic targets for cancer and inflammatory diseases.
  • Advanced AI will be combined with spatial omics data to detect critical patterns across large datasets, potentially leading to new diagnostics and personalized treatment plans.

Elix and LINC Launch World's First Commercial AI Drug Discovery Platform Using Federated Learning from 16 Pharmaceutical Companies

AIDrug Discovery
  • Elix and LINC have commercialized the world's first AI drug discovery platform incorporating federated learning models trained on data from 16 pharmaceutical companies, addressing the critical data scarcity challenge in AI drug discovery.
  • The platform leverages over 1 million compounds and 10 million data points through the kMoL federated learning library, enabling collaborative AI model development while preserving confidential pharmaceutical data.
  • The initiative emerged from Japan's AMED DAIIA project and includes AI models for on/off-target prediction, ADMET prediction, and molecular generation, with several pharmaceutical companies already adopting the Elix Discovery™ platform.
  • The commercialization represents a significant milestone in pharmaceutical AI, positioning the platform to become the de-facto standard for AI drug discovery in Japan while contributing to enhanced drug development capabilities globally.

Biophytis Partners with Lynx Analytics to Accelerate AI-Driven Drug Discovery for Sarcopenia

AIDrug Discovery
  • Biophytis SA has announced a strategic partnership with Lynx Analytics to leverage artificial intelligence for accelerating small molecule drug discovery targeting sarcopenia, a condition with no FDA-approved treatments.
  • The collaboration will combine Biophytis' expertise in age-related disease biology with Lynx's advanced AI platforms to identify and optimize compounds for muscle preservation and regeneration.
  • The partnership aims to significantly reduce development time and costs while building a robust pipeline of drug candidates to restore muscle function for sarcopenia patients.

Wockhardt Exits US Generics Business to Focus on Novel Antibiotic Drug Discovery

Drug Discovery
  • Wockhardt Ltd has filed for voluntary liquidation of its US subsidiaries Morton Grove Pharmaceuticals Inc. and Wockhardt USA LLC under Chapter 7 of the US Bankruptcy Code to exit its loss-making generics business.
  • The company's US generics business incurred nearly $8 million in losses in FY25 and has been unprofitable for several years, prompting the strategic exit.
  • Wockhardt is pivoting to focus on its novel antibiotic drug discovery program, with six candidates in development targeting drug-resistant bacterial infections.
  • The company's lead antibiotic candidate Zaynich has completed global phase 3 trials and has an addressable market potential of $7 billion in the US and Europe.

Microsoft Launches BioEmu AI System to Accelerate Drug Discovery Through Protein Simulation

AIDrug Discovery
  • Microsoft has introduced BioEmu, an AI system that can predict protein structural changes and movements in hours rather than the years typically required for traditional computer simulations.
  • The system achieves prediction errors of less than 1 kcal/mol and correlation scores above 0.6 on large test datasets, demonstrating high accuracy in matching real-world experimental protein stability data.
  • BioEmu can generate thousands of protein structures per hour using just one GPU, offering a scalable and cost-effective alternative to traditional molecular dynamics simulations.
  • The AI system can identify cryptic binding pockets in proteins, which are hidden drug target sites that could lead to the development of new therapeutic compounds.

TandemAI and Perpetual Medicines Merge to Advance AI-Driven Small Molecule and Peptide Drug Discovery

AIDrug Discovery
  • TandemAI and Perpetual Medicines have completed a strategic merger to create an expanded AI and physics-based drug discovery platform covering both small molecules and peptides.
  • The combined company will leverage TandemAI's proven track record with over 150 pharmaceutical partners and Perpetual's computational peptide discovery platform to accelerate therapeutic development.
  • More than ten client programs from TandemAI are expected to reach clinical trials within the next 12 months, demonstrating the commercial viability of their AI-driven approach.
  • The merger positions the combined entity to capitalize on the growing commercial opportunity in peptide therapeutics, particularly following the success of GLP-1, IL-23, and PCSK9 drug classes.

Renovaro Biosciences Converts $9.7M Debt to Equity, Strengthens AI-Driven Drug Discovery Platform

AIPrecision MedicineDrug Discovery
  • Renovaro Inc. (NASDAQ:RENB) announced that senior debt holders agreed to convert approximately $9.7 million of outstanding debt into equity through the issuance of 53.6 million shares at $0.30 per share.
  • The debt conversion significantly enhances the company's balance sheet by eliminating debt obligations and interest payments, providing greater financial flexibility for growth initiatives.
  • The biotechnology company focuses on AI-driven precision medicine, developing innovative therapies and diagnostics in oncology, infectious disease, and autoimmune disorders using machine learning integrated with biomedical research.

Xaira Therapeutics Appoints Jeff Jonker as President and COO to Scale AI-Driven Drug Discovery Platform

AIDrug Discovery
  • Xaira Therapeutics has appointed biotech veteran Jeff Jonker as President and Chief Operating Officer to help scale its AI-enabled drug discovery platform and drive the next phase of growth.
  • Jonker brings over two decades of leadership experience, having served as CEO of Belharra Therapeutics and Ambys Medicines, and President of NGM Biopharmaceuticals where he formed strategic partnerships with Merck.
  • The appointment comes as Xaira aims to fundamentally reimagine drug discovery by integrating machine learning, biological insight, and therapeutic development to accelerate medicine discovery.
  • Xaira recently published the X-Atlas/Orion dataset, profiling over 8 million single cells as the largest publicly available genome-wide Perturb-seq dataset to power next-generation foundation models in biology.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.